528593-71-7 Usage
Uses
Used in Pharmaceutical Industry:
5-[(1-Indolyl)Methyl]-3-Methylisoxazole is used as a pharmaceutical agent for its potential anti-inflammatory properties, making it a candidate for the treatment of various inflammatory conditions. Its capacity to modulate inflammatory responses could provide relief and management of symptoms associated with such disorders.
Used in Oncology:
In the field of oncology, 5-[(1-Indolyl)Methyl]-3-Methylisoxazole is utilized as an antitumor agent. Its potential to interfere with cancer cell growth and proliferation suggests that it could be a valuable component in the development of new cancer therapies, offering an alternative or complementary approach to existing treatments.
Used in Neurological Applications:
5-[(1-Indolyl)Methyl]-3-Methylisoxazole is also considered for use in treating neurological disorders due to its potential neuroprotective effects. 5-[(1-Indolyl)Methyl]-3-Methylisoxazole's ability to interact with neurological pathways and processes may contribute to the management or mitigation of symptoms in various neurodegenerative or neuroinflammatory conditions.
Used in Drug Development Research:
As a compound with multiple biological activities, 5-[(1-Indolyl)Methyl]-3-Methylisoxazole is used in drug development research to explore its therapeutic potential across different medical fields. Ongoing studies aim to understand its mechanisms of action, optimize its delivery, and assess its safety and efficacy for clinical use.
Check Digit Verification of cas no
The CAS Registry Mumber 528593-71-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,2,8,5,9 and 3 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 528593-71:
(8*5)+(7*2)+(6*8)+(5*5)+(4*9)+(3*3)+(2*7)+(1*1)=187
187 % 10 = 7
So 528593-71-7 is a valid CAS Registry Number.
528593-71-7Relevant articles and documents
Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents
Li, Wen-Tai,Hwang, Der-Ren,Chen, Ching-Ping,Shen, Chien-Wei,Huang, Chen-Long,Chen, Tung-Wei,Lin, Chi-Hung,Chang, Yee-Ling,Chang, Ying-Ying,Lo, Yue-Kan,Tseng, Huan-Yi,Lin, Chu-Chung,Song, Jeng-Shin,Chen, Hua-Chien,Chen, Shu-Jen,Wu, Se-Hui,Chen, Chiung-Tong
, p. 1706 - 1715 (2007/10/03)
A series of N-heterocyclic indolyl glyoxylamides were synthesized and evaluated for in vitro and in vivo anticancer activities. They exhibited a broad spectrum of anticancer activity not only in murine leukemic cancer cells but also in human gastric, breast, and uterus cancer cells as well as their multidrug resistant sublines with a wide range of IC50 values. They also induced apoptosis and caused DNA fragmentation in human gastric cancer cells. Among the compounds studied, 7 showed the most potent activity of growth inhibition (IC50 17-1711 nM) in several human cancer cells. Given orally, compounds 7 and 13 dose-dependently prolonged the survival of animals inoculated with P388 leukemic cancer cells. N-Heterocyclic indolyl glyoxylamides may be useful as orally active chemotherapeutic agents against cancer and refractory cancerous diseases of multidrug resistance phenotype.
